Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 4
1989 2
1990 1
1991 2
1992 3
1993 1
1994 2
1995 2
1997 1
1998 3
1999 6
2000 6
2001 6
2002 1
2003 5
2004 2
2005 4
2006 2
2007 9
2008 5
2009 3
2010 4
2011 14
2012 5
2013 5
2014 8
2015 11
2016 13
2017 10
2018 16
2019 8
2020 9
2021 9
2022 7
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Abifadel M, et al. Among authors: farnier m. Nat Genet. 2003 Jun;34(2):154-6. doi: 10.1038/ng1161. Nat Genet. 2003. PMID: 12730697
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.
Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgözoglu L, Zambon A, Berrou JP, Farnier M. Raja V, et al. Among authors: farnier m. Atherosclerosis. 2023 Oct;383:117312. doi: 10.1016/j.atherosclerosis.2023.117312. Epub 2023 Sep 30. Atherosclerosis. 2023. PMID: 37826864 Free article. Review.
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP).
Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, Paneni F, Parini P, Pirro M, Reiner Ž, Vrablik M, Escobar C. Banach M, et al. Among authors: farnier m. Prog Cardiovasc Dis. 2023 Jul-Aug;79:2-11. doi: 10.1016/j.pcad.2023.03.001. Epub 2023 Mar 7. Prog Cardiovasc Dis. 2023. PMID: 36889490 Free article. Review.
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Robinson JG, et al. Among authors: farnier m. N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031. Epub 2015 Mar 15. N Engl J Med. 2015. PMID: 25773378 Free article. Clinical Trial.
PCSK9 inhibitors.
Farnier M. Farnier M. Curr Opin Lipidol. 2013 Jun;24(3):251-8. doi: 10.1097/MOL.0b013e3283613a3d. Curr Opin Lipidol. 2013. PMID: 23652470 Review.
Statin combination therapy and cardiovascular risk reduction.
Toth PP, Farnier M, Tomassini JE, Foody JM, Tershakovec AM. Toth PP, et al. Among authors: farnier m. Future Cardiol. 2016 May;12(3):289-315. doi: 10.2217/fca-2015-0011. Epub 2016 Apr 15. Future Cardiol. 2016. PMID: 27079178 Review.
PCSK9: From discovery to therapeutic applications.
Farnier M. Farnier M. Arch Cardiovasc Dis. 2014 Jan;107(1):58-66. doi: 10.1016/j.acvd.2013.10.007. Epub 2013 Dec 27. Arch Cardiovasc Dis. 2014. PMID: 24373748 Free article. Review.
Combination therapy in dyslipidemia: where are we now?
Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tershakovec AM. Catapano AL, et al. Among authors: farnier m. Atherosclerosis. 2014 Nov;237(1):319-35. doi: 10.1016/j.atherosclerosis.2014.09.026. Epub 2014 Sep 30. Atherosclerosis. 2014. PMID: 25299967 Review.
187 results